Takecab Faces 2nd “Huge-Seller” Price Slash, All GLP-1 Injectables to Get Cut Too on Market Expansion

Takeda Pharmaceutical’s proton pump inhibitor (PPI) Takecab (vonoprazan) is expected to face a price slash under so-called “huge-seller” re-pricing in April 2022, along with its combo medicines as similar drugs, Jiho has learned. At the same time, Novo Nordisk’s GLP-1...read more